Bristol-Myers Squibb, CHECKMATE-76K, FDA, melanoma, Ajoyib
Nivolumab FDA tomonidan IIB/C bosqich melanomasini adjuvant davolash uchun tasdiqlangan
Nov 2023: Nivolumab (Opdivo, Bristol-Myers Squibb Company) was granted approval by the Food and Drug Administration as an adjuvant therapy for Stage IIB/C melanoma in patients 12 years of age and older who had undergone complete..
BMS, Bristol Mayers Squibb, immünoterapi, metastatik melanoma, nivolumab va relatlimab, nivolumab va relatlimab-rmbw, Opdualag, USFDA
Birinchi LAG-3-bloklovchi antikor birikmasi Opdualag ™ (nivolumab va relatlimab-rmbw) rezektsiya qilinib bo'lmaydigan yoki metastatik melanomasi bo'lgan bemorlar uchun FDA tomonidan tasdiqlangan.
2022 yil aprel: AQSh oziq-ovqat va farmatsevtika idorasi (FDA) Opdualagni (nivolumab va relatlimab-rmbw) tasdiqladi, yangi, birinchi sinfdagi nivolumab va relatlimabning yagona vena ichiga infuzion sifatida yuboriladigan qat'iy dozali kombinatsiyasi, f.
Immunocore Limited, Kimmtrak, metastatik uveal melanoma, tebentafusp-tebn, uveal melanoma
Tebentafusp-tebn rezektsiya qilinmaydigan yoki metastatik uveal melanoma uchun tasdiqlangan
2022-yil mart: Tebentafusp-tebn (Kimmtrak, Immunocore Limited), bispesifik gp100 peptid-HLA-yo'naltirilgan CD3 T-hujayra bilan shug'ullanuvchi, oziq-ovqat va farmatsevtika idorasi tomonidan HLA-A*02:01-musbat kattalar uchun rezektsiyasiz bemorlar uchun litsenziyalangan. .
CD-38, FDA, HORIZON, immunomodulyator, melfalan flufenamid, ko'p mieloma, NCT02963493, Onkopeptidlar AB, Pepaxto
Melfalan flufenamid FDA tomonidan relapsli yoki refrakter multipl miyelom uchun ruxsat oladi
2021 yil avgust: Melfalan flufenamid (Pepaxto, Onkopeptidlar AB) deksametazon bilan birgalikda oziq -ovqat va farmatsevtika idorasi tomonidan relapsli yoki refrakter ko'p myelli katta yoshli bemorlar uchun tez tasdiqlangan.
KEYTRUDA, Tashkilot,, NCT02362594, Pembrolizumab, QABUL QILING, USFDA
Pembrolizumab melanomani yordamchi davolash uchun FDA tomonidan tasdiqlangan
15-yil 2019-fevralda pembrolizumab (KEYTRUDA, Merck) oziq-ovqat va farmatsevtika idorasi tomonidan to‘liq rezektsiyadan so‘ng limfa tugunlari (tugunlari) ishtirokida melanoma bilan og‘rigan bemorlarni adjuvant davolash uchun tasdiqlangan. Tasdiqlash ..
Bariatrik jarrohlik, Dehli, Hindiston, AQSH
Bariatrik jarrohlik melanoma xavfini kamaytirishi mumkin
Tezda va davomli vazn yo'qotish va sog'liq uchun boshqa foydali narsalardan tashqari, bariatrik jarrohlik hozirgi kunda malign melanoma xavfining 61% kamayishi bilan bog'liq bo'lib, bu haddan tashqari s bilan eng xavfli o'lik teri saratoni hisoblanadi.